1. Introduction
===============

Feline immunodeficiency virus (FIV) is a lentivirus that causes chronic and progressive acquired immunodeficiency syndrome in domestic cats resembling human immunodeficiency virus (HIV) infection in humans ([@BIB88], [@BIB95]). FIV has been reported worldwide with a prevalence rate ranging from 1 to 28% ([@BIB59], [@BIB113]). Similar to HIV-1 with at least nine subtypes or clades (clades A--D, F--H, J, and K) in the predominant group M, FIV has been classified into five clades (clades A--E) with much smaller intraclade heterogeneity ([@BIB2], [@BIB58], [@BIB111], [@BIB6]). Although in the same Retrovirinae family as the oncovirus, feline leukemia virus (FeLV), FIV more closely resembles HIV in morphology, pathogenesis, and genetic sequence ([@BIB5], [@BIB112]). As a result of the increase in worldwide prevalence and severity of the disease, the development of an effective vaccine is imperative for veterinary medicine ([@BIB27], [@BIB5]). However, effective FIV vaccine development faces similar challenges and obstacles involving broad cross-subtype protection, individual mutations, and inter-subtype recombination, as does effective HIV vaccine development. This paper reviews the clinical disease manifestations produced by FIV infection, similar difficulties experienced with other controversial veterinary vaccines designed to protect both B-cells and T-cells, multiple approaches used to develop an effective FIV vaccine, and the process involved during the development of the first USDA approved commercial dual-subtype FIV vaccine.

2. Pathogenesis and infection
=============================

The hallmark of infection is depletion of CD4^+^ peripheral T-cells and reduction of CD4/CD8 ratios ([@BIB1], [@BIB100], [@BIB104], [@BIB47]). Decreased CD4^+^ T-cell counts in infected cats have been reported in both natural and experimental infections ([@BIB1], [@BIB47]). However, select FIV vaccine strains consistently produce clinical illness characterized by recurrent high fever, increased incidence of secondary infection, leukopenia, CD4 loss, and CD4/CD8 inversion ([@BIB11], [@BIB22]). Even with the loss of CD4^+^ T-cells, cytotoxic T-lymphocyte (CTL) activities develop early in FIV infections and persist during the asymptomatic stage, similar to HIV-1 infections ([@BIB96]). These anti-FIV CTL activities are generally mediated by CD8^+^ T-cells and recognize whole virus and FIV Gag and Env proteins ([@BIB33], [@BIB71]). In addition, CD8^+^ T-cells from FIV-infected cats produced soluble suppressor antiviral factors resembling the CD8-mediated antiviral factor (CAF) produced in HIV-positive individuals ([@BIB34], [@BIB16]). Infected cats possess strong T-helper activities (increased gamma interferon and IL-10 production), during early stages of FIV infection which gradually decrease with long-term infection ([@BIB3], [@BIB104], [@BIB47], [@BIB5], [@BIB72]). These T-cell dysfunctions and responses in FIV-infected cats closely mimic those of HIV-positive individuals ([@BIB91], [@BIB38]). B-cell dysfunctions involving suppressed primary antibody response (first time the antigen is presented to the B-cells) are less dramatic than T-cell dysfunctions (CD4 loss and CD4/CD8 inversion), and seem to be only in primary antibody responses to T-dependent antigens ([@BIB100], [@BIB104]). Virus neutralizing (VN) antibodies to FIV develop shortly after the production of anti-FIV CTL and provide additional immunity ([@BIB57]). Nevertheless, FIV infections persist in the infected animal and steadily destroy the immune system. Interestingly, elevated serum IgG levels are observed in infected cats, indicative of FIV-induced virus-specific B-cell hyperactivity similar to that observed in HIV ([@BIB51], [@BIB1]). High-grade B-cell lymphomas at abnormal sites have also been reported in cats with natural and experimental FIV infections ([@BIB103], [@BIB12]). Thus, the FIV-induced immunological disease is paradoxical since the hyperimmunoactive state occurs shortly before or concurrently with the severe immunodeficiency syndrome in the infected animals. This presentation of the immune disorders closely resembles the presentation in human AIDS ([@BIB10]).

Symptoms most frequently observed in clinical cases of FIV infection are relatively mild and innocuous, including gingivitis, lymphadenopathy, and marginal leukopenia ([@BIB113], [@BIB17], [@BIB43]). The long asymptomatic phase generally persists for years during which time the immune system becomes progressively damaged until the infected animal develops persistent secondary diseases. These secondary infections frequently become resistant to antimicrobial therapy and eventually result in death ([@BIB113]). Long-term survivors have been reported for FIV-infected cats similar to the long-term non-progressors reported for HIV-positive individuals ([@BIB5], [@BIB48]). The long-term survivors appear to make up a sizable population of naturally infected pet cats which can survive for many years with minimal clinical disease. In contrast, higher and earlier mortality rates have been reported in infected stray cats as a result of higher exposure to secondary infections that exacerbate the FIV disease ([@BIB113]). The similarity between HIV and FIV in the disease manifestations and progression of viral infection promotes the use of FIV infection in cats as a model for identifying effective HIV vaccine strategies.

3. Potential of developing an effective AIDS lentivirus vaccine
===============================================================

In order to protect the household indoor/outdoor pet cat population from FIV infection and to control the increasing worldwide prevalence within reservoir stray cat populations, vaccine development is essential. However, efficacious vaccine immunity is dependent upon a healthy immune system. Both FIV and HIV-1 invade and destroy monocyte/macrophage and select T-cell populations within the immune system, mutate within the infected host cells, and create diverse strains with varying pathogenic characteristics. In addition, FIV infects B-cells ([@BIB26]). Consequently, vaccine development becomes increasingly difficult to achieve giving rise to major concerns regarding the development of a safe, efficacious product.

Similar questions arose with the earlier development of other commercial veterinary vaccines, such as the FeLV vaccine (Leukocell^®^, SmithKline Beecham/Pfizer Animal Health Group), the feline infectious peritonitis virus (FIPV) vaccine (Primucell^®^, SmithKline/Pfizer Animal Health), the Marek's disease (MD) vaccine in chickens, and the experimental simian immunodeficiency virus (SIV) vaccine. Like FIV, FeLV attacks and destroys B- and T-lymphocytes and monocytes. Originally released in 1985, the initial vaccine exhibited marginal efficacy in experimental challenge studies. Recent studies with newer generation vaccines have demonstrated improved efficacy and safety in controlled experimental trials ([@BIB68], [@BIB50], [@BIB97]), although controversy still exists on the significance of these experimental trials in relation to natural infection ([@BIB86], [@BIB97]). In addition, FeLV vaccines have been associated with vaccine-associated fibrosarcoma. Tumor formation has been attributed to a hyperproliferative state caused by excessive immunization with vaccines formulated in alum hydroxide based adjuvants ([@BIB97], [@BIB45]). This adjuvant has been considered the probable cause of vaccine-associated fibrosarcoma formation in cats ([@BIB45]). Moreover, a new survey consisting of 31,671 cats from USA and Canada indicates that the incidence of vaccine-associated fibrosarcoma (0.63/10,000 cats) is lower than previously reported 1/10,000 cats and is not increasing ([@BIB42]). Nevertheless, more studies will be needed to resolve this issue. Consequently, FeLV vaccination is generally not recommended for cats living indoors with a minimal risk of contracting the disease ([@BIB76], [@BIB97], [@BIB29]).

Similar to FIV and HIV-1 in initial target cell infection, the corona virus, FIPV, initially invades monocytes and macrophages producing either a fatal effusive (wet) or non-effusive (dry) form of the disease ([@BIB85]). This controversial feline vaccine released in 1991 (Primucell^®^), consisted of attenuated temperature-sensitive live FIPV. Specific pathogen free (SPF) cats administered with intranasal vaccine exhibited significant efficacy in the manufacturer's study ([@BIB39]), whereas independent experimental studies demonstrated vaccine safety with minimal to no efficacy ([@BIB28], [@BIB93]). In additional studies, enhancement of FIP challenge infection was observed in vaccinated animals ([@BIB94], [@BIB81]).

Like FIV and FeLV, MD virus, an oncogenic herpes virus (serotype 1) specific to chickens, infects T- and B-lymphocytes producing neuropathy and neoplasia ([@BIB13], [@BIB14], [@BIB109]). This virus is highly cell-associated producing the disease only in chickens ([@BIB14]). Contrary to popular scientific belief, vaccination against viruses which infect T- and B-lymphocytes is possible. Used as vaccine antigens, inactivated whole virus and inactivated infected-cell vaccines demonstrated efficacy in experimental and clinical trials ([@BIB13], [@BIB109]). Recent MD vaccines consisting of either live attenuated serotype 1 MD virus or non-pathogenic serotypes 2 or 3 avian herpes viruses, support earlier clinical trial results ([@BIB13]). Consequently, the MD vaccine, the first successful vaccine to effectively control any neoplastic disease in man or animals, lends strong support for the idea that vaccine development is possible against viruses which infect both arms of the immune system (T- and B-lymphocytes) ([@BIB109]). Overall, the FeLV, FIP, and MD vaccines demonstrate that vaccines against viruses that infect and destroy immune cells are difficult to develop. However, the existence of USDA approved vaccines to these viruses in commercial market also provide optimism to the development of an effective FIV vaccine.

Promising results from recent SIV vaccine studies further support the view that vaccines against AIDS lentiviruses can be developed ([@BIB61], [@BIB83], [@BIB82]). A major reduction in SIV disease and virus load was observed in vaccinated macaques using either vector-based vaccines or DNA vaccines with and without cytokine adjuvantation or viral peptide boost ([@BIB61], [@BIB83], [@BIB82]). Partial protection correlated with strong CD8^+^ T-cell responses ([@BIB61], [@BIB83], [@BIB82]). Long-term follow-up of these animals will be required to determine whether the control of virus load and disease progression can be maintained with or without additional vaccination. Although sterilizing immunity was not observed, the virus virulence and viral challenge doses used may be considerably higher than those from a single natural exposure, and may thus represent excellent vaccine approaches for candidate HIV-1 vaccines. Protection against SIV infection has been observed with attenuated deletion mutant vaccines ([@BIB20], [@BIB21], [@BIB110]). However, this approach is considered to be impractical for clinical trials in humans. Results from these preclinical studies raise three important points: (1) vaccine protection against disease is easier to achieve than prevention of infection (i.e., sterilizing immunity); (2) the need to identify the duration of such partial protection; (3) the need to test the vector-based or DNA vaccine approaches against distinctly heterologous subtype clinical isolates.

4. FIV vaccine studies
======================

Recent FIV vaccine trial results (1998 to present) are summarized in [Table 1](#TBL1){ref-type="table"}, [Table 2](#TBL2){ref-type="table"}, [Table 3](#TBL3){ref-type="table"}, [Table 4](#TBL4){ref-type="table"} , whereas earlier vaccine trial results have been reported elsewhere ([@BIB25]). A brief overview of these tables suggests that the majority of success achieved in experimental FIV vaccine trials has been made with inactivated whole virus or inactivated infected-cell conventional vaccines against more severe challenge systems. These severe challenge systems include in vivo-derived inocula, heterologous strains, and clinical isolates. In comparison, viral peptide vaccines have fared poorly ([Table 3](#TBL3){ref-type="table"}, Study 1--4), while DNA vaccines and vector vaccines have shown some promising results against weaker challenge systems.Table 1Inactivated whole virus or whole viral protein vaccinesType of immunizationImmunizationType of adjuvant[a](#TBLFN1){ref-type="table-fn"}Challenge inoculum strain and dose (cell no. and CID~50~) and route[b](#TBLFN2){ref-type="table-fn"}, [c](#TBLFN3){ref-type="table-fn"}, [d](#TBLFN4){ref-type="table-fn"}No. protected/no. challenged (% protected)[\*](#TBLFN9){ref-type="table-fn"}Study no. (Ref.)[e](#TBLFN5){ref-type="table-fn"}Vaccine strains[b](#TBLFN2){ref-type="table-fn"}Route[c](#TBLFN3){ref-type="table-fn"}Protocol (weeks)Whole virusPET (A) + SHI (D)s.c.0, 3, 9FD-1BANG, 10, i.v.4/5 (80)[\*](#TBLFN9){ref-type="table-fn"}Study 1A ([@BIB90])Control (cells or PBS)--s.c.0, 3, 9FD-1BANG, 10, i.v.0/4 (0)Whole virusPET (A) + SHI (D)s.c.0, 3, 9, 12FD-1PET, 50, i.v.4/4 (100)[\*](#TBLFN9){ref-type="table-fn"}Study 1B ([@BIB90])Whole virusPET (A)s.c.0, 3, 9, 12FD-1PET, 50, i.v.1/5 (20)Control (PBS)--s.c.0, 9, 12FD-1PET, 50, i.v.0/5 (0)Whole FIVSHI (D)s.c.0, 3, 9, 12FD-1SHI, 50, i.v.1/3 (33)Control (PBS)--s.c.0, 3, 9, 12FD-1SHI, 50, i.v.0/3 (0)Whole virusGL8 (A)rect (±i.p., in)0, 2, 4CTGL8, 10m, rect0/12 (0)Study 2 ([@BIB31])Control (water)--rect0, 2, 4--GL8, 10m, rect0/4 (0)Whole virus or proteinsM2 (B)s.c.0, 3, 6, 9, 20IFAM2, 10, i.v.11/16 (69)Study 3 ([@BIB79])Control (IFA or none)--s.c.0, 3, 6, 9, 20IFA or noneM2, 10, i.v.7/12 (58)Whole virus[f](#TBLFN6){ref-type="table-fn"}M2 (B)s.c. (±ivag, po)[f](#TBLFN6){ref-type="table-fn"}0, 3, 6, 9, 20IFA ± CTM2, 2×10^4^ cells, ivag4/12 (33)Control (adjuvant)[f](#TBLFN6){ref-type="table-fn"}--s.c. (±ivag, po)[f](#TBLFN6){ref-type="table-fn"}0, 3, 6, 9, 20IFA ± CTM2, 2×10^4^ cells, ivag3/8 (37)[g](#TBLFN7){ref-type="table-fn"}Whole virusPET (A)s.c.0, 3, 6MF59.0PET, 10, i.p.5/5 (100)Study 4 ([@BIB55])Control (adjuvant)--s.c.0, 3, 6MF59.0PET, 10, i.p.1/5 (20)Whole virusPET (A)s.c.0, 3, 6MF59.0GL8, 10, i.p.2/5 (40)Control (adjuvant)--s.c.0, 3, 6MF59.0GL8, 10, i.p.0/5 (0)Whole virusPET (A)s.c.0, 3, 6MF59.0AM6, 10, i.p.3/5 (60)Control (adjuvant)--s.c.0, 3, 6MF59.0AM6, 10, i.p.1/5 (20)Whole virusM2 (B)i.p.0, 4, 8, 12Homol-RBCM2, 10, i.v.4/4 (100)[\*](#TBLFN9){ref-type="table-fn"}Study 5 ([@BIB15])Control (BSA)--i.p.0, 4, 8, 12Homol-RBCM2, 10, i.v.0/4 (0)Whole virus[h](#TBLFN8){ref-type="table-fn"}M2 (B)i.p.0, 4, 8, 12, 16Homol-RBCM2, 10, i.v.0/4 (0)Control (BSA)[h](#TBLFN8){ref-type="table-fn"}--i.p.16Homol-RBCM2, 10, i.v.0/4 (0)[^1][^2][^3][^4][^5][^6][^7][^8][^9]Table 2Infected-cell vaccines (ICV) and recombinant vectored vaccines with and without ICV or SU protein boostsType of immunization[a](#TBLFN10){ref-type="table-fn"}VaccineImmunizationType of adjuvant[b](#TBLFN11){ref-type="table-fn"}Challenge inoculum strain (clade) and dose (CID~50~) and route[c](#TBLFN12){ref-type="table-fn"}, [d](#TBLFN13){ref-type="table-fn"}, [e](#TBLFN14){ref-type="table-fn"}No. protected/no. challenged (% protect)[f](#TBLFN15){ref-type="table-fn"}Study no. (Ref.)[g](#TBLFN16){ref-type="table-fn"}Strain (clade)[c](#TBLFN12){ref-type="table-fn"}Dose (ug)Route[d](#TBLFN13){ref-type="table-fn"}Protocol (weeks)Fixed FIV/FL-4PET (A)2.5×10^7^TLN0, 2, 4Quil APET (A), 100, rect4/4 (100)Study 1 ([@BIB32])Fixed FeT-J--2.5×10^7^TLN0, 2, 4NonePET (A), 100, rect1/4 (25)Fixed FIV/FL-4PET (A)2.5×10^7^TLN0, 2, 4Quil APET (A), 100, rect4/4 (100)Study 2 ([@BIB98])Fixed FeT-J--2.5×10^7^TLN0, 2, 4NonePET (A), 100, rect0/4 (0)Fixed FIV/MBMM2 (B)3×10^7^s.c.0, 3, 6, 16, 40, 64IFAField isol (na), na, contact expo12/12 (100)Study 3 ([@BIB80])Control (none)----------Field isol (na), na, contact expo9/14 (64)Fixed FIV-autoPBMCClone 19k1 (A)5×10^6^i.v. + s.c.0, 2, 4, 6, 8, 16--Clone19k1 (A), 10, i.m.0/3↑ (0)Study 4 ([@BIB62], [@BIB63])Fixed autoPBMC--5×10^6^i.v. + s.c.0, 2, 4, 6, 8, 16--Clone19k1 (A), 10, i.m.0/2 (0)ALVAC-FIVVFr (A)1×10^8^ pfu[h](#TBLFN17){ref-type="table-fn"}i.m.0, 4, 8--PET (A), 50, i.p.0/3 (0)Study 5A ([@BIB102])ALVAC-FIV + ICV[h](#TBLFN17){ref-type="table-fn"}VFr (A)/PET (A)+2×10^8^ cells[h](#TBLFN17){ref-type="table-fn"}i.m. + s.c.0, 4, 8--/SAF-MDPPET (A), 50, i.p.3/3 (100)ALVAC + ICV[h](#TBLFN17){ref-type="table-fn"}--/PET (A)+2×10^8^ cells[h](#TBLFN17){ref-type="table-fn"}i.m. + s.c.0, 4, 8--/SAF-MDPPET (A), 50, i.p.0/3 (0)ALVAC-FIV + ICV[h](#TBLFN17){ref-type="table-fn"}, [i](#TBLFN18){ref-type="table-fn"}VFr (A)/PET (A)+2×10^8^ cells[h](#TBLFN17){ref-type="table-fn"}i.m. + s.c.0, 4, 8--/SAF-MDPBANG (A/B), 75, i.p.[i](#TBLFN18){ref-type="table-fn"}0/3 (0)Control (none)----------BANG (A/B), 75, i.p.[i](#TBLFN18){ref-type="table-fn"}0/3 (0)pCI-NC vector/recSU[j](#TBLFN19){ref-type="table-fn"}GAS (A)/BANG (A/B)300/100in/s.c.0, 15, 30, 45 days[j](#TBLFN19){ref-type="table-fn"}--GAS (A), 1, i.p.1/4 (25)Study 6 ([@BIB18])pCI-NC vector/recSU[j](#TBLFN19){ref-type="table-fn"}GAS (A)/BANG (A/B)300/100i.m./s.c.0, 15, 30, 45 days[j](#TBLFN19){ref-type="table-fn"}--GAS (A), 1, i.p.0/4 (0)pCI vector/recSU[j](#TBLFN19){ref-type="table-fn"}--/BANG (A/B)300/100i.m./s.c.0, 15, 30, 45 days[j](#TBLFN19){ref-type="table-fn"}--GAS (A), 1, i.p.0/4 (0)pCI vector/PBS[j](#TBLFN19){ref-type="table-fn"}--/--300/--i.m./s.c.0, 15, 30, 45 days[j](#TBLFN19){ref-type="table-fn"}--GAS (A), 1, i.p.0/4 (0)[^10][^11][^12][^13][^14][^15][^16][^17][^18][^19]Table 3Solubilized whole virus and viral peptide (synthetic and recombinant) vaccinesType of immunization[a](#TBLFN20){ref-type="table-fn"}VaccineImmunizationType of adjuvant[b](#TBLFN21){ref-type="table-fn"}Challenge inoculum strain (clade) and dose (CID~50~) and route[c](#TBLFN22){ref-type="table-fn"}, [d](#TBLFN23){ref-type="table-fn"}No. protected/no. challenged[e](#TBLFN24){ref-type="table-fn"}Study no. (Ref.)[f](#TBLFN25){ref-type="table-fn"}FIV strain (clade)[c](#TBLFN22){ref-type="table-fn"}Dose (ug)Route[g](#TBLFN26){ref-type="table-fn"}Protocol (weeks)ENV-C2 peptidena200TLN0, 2, 4Quil AGL8 (A), 10m, rectal0/4Study 1 ([@BIB32])ENV-C2 peptidena200Rectal0, 2, 4Quil AGL8 (A), 10m, rectal0/4Control (water)----Rectal0, 2, 4NoneGL8 (A), 10m, rectal0/4MAP V3GL8 (A) and PET (A)200Rectal (±i.p.)0, 2, 4CTGL8 (A), 10m, rectal0/8Study 2A ([@BIB31])MAP V3GL8 (A) and PET (A)200Rectal (±i.p.)0, 2, 4Quil AGL8 (A), 10m, rectal0/8MAP V3GL8 (A) and PET (A)200Rectal0, 2, 4--GL8 (A), 10m, rectal0/4Control (water)----Rectal0, 2, 4--GL8 (A), 10m, rectal0/4ptV3GL8 (A) and PET (A)200s.c.0, 2, 4IFAGL8 (A), 10m, rectal0/4Study 2B ([@BIB31])ptV3GL8 (A) and PET (A)200s.c.0, 2, 4ISCOMsGL8 (A), 10m, rectal0/4V3GL8 (A) and PET (A)200s.c.0, 2, 4CTGL8 (A), 10m, rectal0/4V3GL8 (A) and PET (A)200Rectal (±in)0, 2, 4CTGL8 (A), 10m, rectal0/8Control (water)----s.c.0, 2, 4--GL8 (A), 10m, rectal0/4swFIVAM19 (A)10s.c.0, 4, 10ISCOMsAM19 (A), 20, i.m.0/6Study 3 ([@BIB56])swFIV + SU--TMAM19 (A)10s.c.0, 4, 10ISCOMs (all)AM19 (A), 20, i.m.0/6swFIV + SU--TM + GagAM19/19k1 (A)10s.c.0, 4, 10ISCOMs (all)AM19 (A), 20, i.m.0/5swCrFK--10s.c.0, 4, 10ISCOMsAM19 (A), 20, i.m.0/6SIV-Env--10s.c.0, 4, 10ISCOMsAM19 (A), 20, i.m.0/6Control (PBS)----s.c.0, 4, 10--AM19 (A), 20, i.m.0/6recSU proteinZ2 (A)100s.c.0, 2, 4AlOH + QS-21Z2 (A), 20, i.p.0/5↓Study 4 ([@BIB69])recSU glycoproteinZ2 (A)100s.c.0, 2, 4AlOH + QS-21Z2 (A), 20, i.p.0/5↓recSU glycoproteinZ2 (A)100s.c.0, 2, 4FCA + rabNCZ2 (A), 20, i.p.0/5↓Control (PBS)Z2 (A)100s.c.0, 2, 4--Z2 (A), 20, i.p.0/7[^20][^21][^22][^23][^24][^25][^26]Table 4DNA vaccinesType of immunization[a](#TBLFN27){ref-type="table-fn"}VaccineImmunizationType of adjuvant[b](#TBLFN28){ref-type="table-fn"}Challenge inoculum strain and dose (CID~50~) and route[c](#TBLFN29){ref-type="table-fn"}, [d](#TBLFN30){ref-type="table-fn"}, [e](#TBLFN31){ref-type="table-fn"}No. protected/no. challenged[f](#TBLFN32){ref-type="table-fn"}Study no. (Ref.)[g](#TBLFN33){ref-type="table-fn"}Strain (clade)[c](#TBLFN29){ref-type="table-fn"}Route[h](#TBLFN34){ref-type="table-fn"}, [d](#TBLFN30){ref-type="table-fn"}Protocol (weeks)Proviral DNA DINGL8 (A)i.m.0, 4, 8--PET, 25, i.p.1/6Study 1A ([@BIB23])Proviral DNA DINGL8i.m.0, 4, 8IL-18 DNAPET, 25, i.p.2/6Proviral DNA DINGL8i.m.0, 4, 8IL12/IL18 DNAPET, 25, i.p.2/6Proviral DNA DRTGL8i.m.0, 4, 8IL-18 DNAPET, 25, i.p.2/6Proviral DNA DRTGL8i.m.0, 4, 8IL12/IL18 DNAPET, 25, i.p.0/6Control (pBR328)--i.m.0, 4, 8IL12/IL18 DNAPET, 25, i.p.0/6Proviral DNA DINGL8 (A)i.m.0, 4, 8, 32--PET, 25, i.p. (second)[j](#TBLFN36){ref-type="table-fn"}1/1Study 1B ([@BIB23])Proviral DNA DINGL8i.m.0, 4, 8, 32IL-18 DNAPET, 25, i.p. (second)[j](#TBLFN36){ref-type="table-fn"}2/2Proviral DNA DINGL8i.m.0, 4, 8, 32IL12/IL18 DNAPET, 25, i.p. (second)[j](#TBLFN36){ref-type="table-fn"}1/1Proviral DNA DRTGL8i.m.0, 4, 8, 32IL-18 DNAPET, 25, i.p. (second)[j](#TBLFN36){ref-type="table-fn"}0/1Control (pBR328)[i](#TBLFN35){ref-type="table-fn"}--i.m.(32)[i](#TBLFN35){ref-type="table-fn"}IL12/IL18 DNAPET, 25, i.p.0/4Proviral DNA DINGL8 (A)i.m.32, 61--GL8, 10, i.p. (third)[j](#TBLFN36){ref-type="table-fn"}0/1↓Study 1C ([@BIB23])Proviral DNA DINGL8i.m.32, 61IL-18 DNAGL8, 10, i.p. (third)[j](#TBLFN36){ref-type="table-fn"}0/2↓Proviral DNA DINGL8i.m.32, 61IL12/IL18 DNAGL8, 10, i.p. (third)[j](#TBLFN36){ref-type="table-fn"}0/1↓Control (PBS)[i](#TBLFN35){ref-type="table-fn"}--i.m.(61)[i](#TBLFN35){ref-type="table-fn"}--GL8, 10, i.p.0/4gp140 DNA MIDGEZ2 (A)i.e.0, 3, 6IL-12 DNA MIDGE25 TCID~50~, Z23/4↓Study 2 ([@BIB8], [@BIB70])gp140 DNA MIDGEZ2i.e.0, 3, 6IL-16 DNA MIDGE25 TCID~50~, Z20/4↓gp140 DNA MIDGEZ2i.e.0, 3, 6CpGs25 TCID~50~, Z20/4↓gp140 DNA MIDGEZ2i.e.0, 3, 6--25 TCID~50~, Z20/4Control (gold particle)Z2i.e.0, 3, 6--25 TCID~50~, Z20/4Proviral DNA DVIFPPRi.m.0, 43--PPR3/3Study 3 ([@BIB74])Control (media)--i.m.0, 43--PPR0/2Proviral DNA DRTPET (A)i.m.0, 4, 8IFN-g DNA10 PET1/6Study 4 ([@BIB55])Proviral DNA DRTGL8 (A)i.m.0, 4, 8IFN-g DNA10 PET2/6Control (adjuvant)--i.m.0, 4, 8IFN-g DNA10 PET0/6Proviral DNA DRTPETi.m.0, 4, 8IFN-g DNA10 GL80/6Proviral DNA DRTGL8i.m.0, 4, 8IFN-g DNA10 GL80/6Control (adjuvant)--i.m.0, 4, 8IFN-g DNA10 GL81/6Proviral DNA DRTPET (F-14)i.m.0, 10, 23IFN-g DNA25, F-143/5Study 5 ([@BIB54])Proviral DNA DRTPET (F-14)i.m.0, 10, 23--25, F-141/5Control (adjuv/none)PET (F-14)i.m.0, 10, 23/noneIFN-g DNA or none25, F-140/10Proviral DNA DRTPET (F-14)i.m.0, 4, 8IFN-g DNA25, F-142/5Control (adjuvant)PET (F-14)i.m.0, 4, 8IFN-g DNA25, F-140/5Proviral DNA DAP-1TM2ivag0--5×10^6^ cells, TM22/2Study 6 ([@BIB66])Control (none)--------5×10^6^ cells, TM20/3[^27][^28][^29][^30][^31][^32][^33][^34][^35][^36]

Vaccine prophylaxis is influenced not only by the FIV strains used as vaccine antigens but also by the strain and source of the challenge inoculum. Multiple laboratories have demonstrated that single-strain FIV vaccine can protect cats against homologous (same strain) and slightly heterologous (different strain) FIV challenges of the same subtype ([@BIB114], [@BIB25], [@BIB55]). In contrast, few studies show enhancement of FIV infection even against homologous challenge ([@BIB52], [@BIB25], [@BIB63]). Technical differences in vaccine inactivation procedure, cell types used for growing vaccine virus, vaccination schedule, adjuvant used, vaccine doses, and variable virulence between FIV strains have produced conflicting results in vaccine efficacy studies ([@BIB55]). In one study, inactivated whole virus vaccinated cats exhibited greater protection against in vitro-derived homologous challenge (FIV~PET~) compared to more virulent heterologous FIV challenge (FIV~AM6~, FIV~GL8~) ([@BIB55]). Nevertheless, even with virulent challenge strains, significant reductions in virus load and early inverted CD4/CD8 ratios were observed in these whole virus vaccinated cats compared to unvaccinated control or DNA-based vaccinated cats. However, other investigators have reported partial protection against homologous challenge with FIV DNA vaccine in other FIV strains ([@BIB8], [@BIB74]).

Inactivated single-strain (whole virus) vaccine protection has been reported using in vivo-derived inoculum against challenges with homologous FIV strains but not against in vivo-derived challenges with heterologous FIV strains ([@BIB46], [@BIB77], [@BIB90]). Single-strain vaccines have only provided adequate protection against homologous and closely related strains but not against moderately to greatly heterologous FIV strains ([@BIB53], [@BIB25], [@BIB46]). To date, conventional inactivated single-subtype FIV vaccines and molecular-derived vaccines (plasmid DNA, recombinant vectored, recombinant peptide vaccines) have been untested or unsuccessful at protecting cats against heterologous subtype FIV challenges using in vivo-derived inoculum ([@BIB25]). Recent studies suggest that homologous FIV vaccine protection using in vitro-derived inoculum challenges may not provide protection against challenges using in vivo-derived inoculum ([@BIB46], [@BIB77], [@BIB90]). In vivo-derived inoculum consists of plasma or infected-cells derived from cats infected with in vivo passaged laboratory isolates which contain quasi-species of FIV and closely simulate natural conditions. In a study using single-subtype FIV vaccine consisting of fixed infected-cell FIV~M2~ isolate, SPF cats were protected against homologous FIV challenge with in vivo-derived inoculum ([@BIB77]). When placed in a free-roaming shelter for 22 months with natural FIV-infected cats, this single-subtype vaccine protected the vaccinated group of cats (0/12 FIV infection rate) whereas 5/14 of the unvaccinated control group became infected ([@BIB80]). A major limitation of inactivated infected-cell vaccines is the short duration of vaccine immunity compared to inactivated whole virus vaccines ([@BIB78], [@BIB102]). Since the level of the FIV exposure during natural transmission remains unknown, the efficacy evaluation using a contact challenge system represents the ultimate test for any commercial FIV vaccine. Consequently, a modified approach to single-strain FIV vaccine designs may be required for developing a vaccine that can provide broad spectrum protection against common FIV subtypes (A and B) and in vivo-derived inoculum.

As demonstrated by the synergistic protective properties of the multi-serotype inactivated whole virus MD vaccines, the use of multi-serotype/multi-subtype vaccines is not a novel idea in veterinary medicine ([@BIB109]). The multi-subtype vaccine approach to broaden immunity and protection was first introduced to the AIDS vaccine community using an FIV vaccine model ([@BIB115]). The first dual-subtype FIV vaccine, consisting of inactivated subtype A- and subtype D-infected-cells, provided protection against in vitro-derived homologous strains but was not tested against heterologous strains ([@BIB115], [@BIB49]). An improved dual-subtype FIV vaccine, consisting of inactivated whole viruses of subtypes A and D, elicited strong anti-FIV cellular immunity and broad spectrum VN antibody activities ([@BIB90]). In addition, it provided broadened protection for cats against homologous and heterologous challenges using in vivo-derived inoculum ([@BIB90]). However, this FIV vaccine has not yet been field tested against natural-exposed FIV-infected animals. The precedent for using a whole virus vaccine in cats has been established with FeLV vaccine. No known cases of accidental infection due to improper inactivation of the virus have been reported with FeLV vaccines. With improved inactivation methods of vaccine virus and better adjuvant formulations, inactivated or killed vaccine approach will continue to be useful in future veterinary vaccine development.

5. Immune correlate of vaccine protection
=========================================

Until recently, most veterinary vaccines were developed to provide protection via induction of antiviral humoral immunity, specifically VN antibodies. This VN antibody approach was also used in early HIV/SIV vaccine development. However, a failure to experimentally demonstrate protection using surface envelope-based vaccines in non-human primates and a lack of correlation between VN antibody production and protection, dampened enthusiasm towards developing a vaccine that relies mainly on antibody immunity ([@BIB61], [@BIB83], [@BIB82]). Subsequently, the AIDS vaccine community modified their view by advocating the concept that an efficacious vaccine against AIDS viruses will require strong antiviral cellular immunity to confer protection ([@BIB61], [@BIB83], [@BIB82]). Consequently, developing vaccines which induce cellular immunity for protection such as recombinant vectored vaccines and DNA vaccines became the primary focus for AIDS vaccine research ([@BIB61], [@BIB83], [@BIB92], [@BIB82]).

DNA vaccines primarily elicit cellular immunity, whereas recombinant vectored vaccines elicit cellular immunity and additional antibodies aimed at the specific targeted proteins ([@BIB61], [@BIB83], [@BIB92], [@BIB82]). Antibody levels are dependent upon the physicochemical character and the expression level of the non-vector targeted proteins. Reduction of virus load and prevention of disease signs/symptoms were observed in animals immunized with DNA vaccines, although complete protection was not achieved in either the HIV- or SIV-infected non-human primate models or FIV-infected domestic cats ([@BIB54], [@BIB61], [@BIB83], [@BIB82]). Since a single identifiable immune correlate of vaccine protection has eluded AIDS researchers for almost two decades, a more comprehensive prime-boost approach incorporating both humoral and cellular immunity was developed against AIDS lentiviruses. This new vaccine approach generally involves priming with the DNA or the recombinant vectored vaccine followed by a viral-vectored or viral subunit protein boost which induces both cellular and antibody immunity ([@BIB61], [@BIB83], [@BIB92], [@BIB82]).

Current findings from AIDS vaccine research suggest that CD4^+^ T-helper, CD8^+^ T-cell, and CTL activity is important for vaccine immunity ([@BIB61], [@BIB83], [@BIB82]). CTL and strong T-helper activity against FIV has been observed with DNA, recombinant vectored, and inactivated whole virus vaccines ([@BIB33], [@BIB101], [@BIB74], [@BIB90], [@BIB23]). Among these FIV vaccine designs, VN antibody induction was more consistent in cats immunized with conventional inactivated virus vaccine followed by recombinant vectored vaccine ([@BIB102], [@BIB40], [@BIB90]). Although, inactivated infected-cell vaccine may induce higher VN antibody levels compared to inactivated whole virus vaccine, the duration of protection may be shorter in the inactivated infected-cell vaccine group ([@BIB78]). Unlike human AIDS research which test HIV vaccine antibodies for their ability to neutralize both laboratory and clinical isolates, FIV vaccine researchers have not tested their vaccine antibodies against non-adapted clinical isolates ([@BIB78], [@BIB90]). FIV laboratories now test the cross-neutralizing ability of sera from naturally and experimentally infected cats against clinical and laboratory isolates ([@BIB58], [@BIB90]). This laboratory testing for neutralizing antibody against non-adapted clinical isolates may become a valuable mechanism for evaluating the cross-strain efficacy of future commercial FIV vaccines.

Like HIV, the detection and titer of VN antibodies to FIV are affected by the type of indicator cells (lymphoid cell lines vs. non-lymphoid CrFK cell lines) used in the VN assay ([@BIB40]). For FIV VN assays, lymphoid cell lines have been reported to produce a more accurate titer during natural infection ([@BIB40]). Cross-neutralizing antibody analysis against clinical isolates have not been performed on sera from cats immunized with candidate FIV vaccines (inactivated dual-subtype virus vaccine and inactivated FIV~M2~-infected-cell vaccine) ([@BIB77], [@BIB80], [@BIB90]). Both candidate vaccines reportedly protected cats against either in vivo-derived heterologous subtype FIV strains or contact challenge with natural isolates ([@BIB77], [@BIB80], [@BIB90]). However, VN antibody titer analysis has been conducted for homologous (FIV~M2~) virus using the inactivated FIV~M2~-infected-cell vaccine sera ([@BIB40]). In this study, protection correlated with the presence of higher VN antibody titer ([@BIB40]). Using sera from inactivated dual-subtype FIV vaccinated cats, a limited number of homologous and heterologous laboratory isolates were tested for cross-neutralizing antibodies ([@BIB90]). Increased types and levels of VN antibodies to heterologous laboratory isolates were reported with the dual-subtype FIV vaccine compared to single-subtype vaccines, further supporting the current concept of AIDS lentiviral vaccine protection requiring both arms of immunity ([@BIB90]).

6. Implication of challenge studies
===================================

Unlike earlier efficacy studies of commercial FeLV vaccines, newly developed FIV vaccines have come under increased scrutiny due to recent advances in human and non-human primate AIDS research, including technical improvements in virus detection methods and increased understanding of challenge conditions upon vaccine efficacy ([@BIB46], [@BIB40], [@BIB90]). The demonstration of protection against both homologous and heterologous challenges has become a standard feature of AIDS lentivirus vaccine development for commercial veterinary use. USDA approved, veterinary vaccines are dependent upon demonstrating efficacy using laboratory grown challenge inoculum. In HIV/SIV studies with non-human primates and in vitro studies, molecular cloned and laboratory isolates did not accurately reflect the immunogenicity and virological activity reported for clinical isolates ([@BIB19], [@BIB4]). Furthermore, inactivated whole virus SIV vaccine studies revealed the need to use challenge inoculum grown in different cells from the vaccine virus in order to prevent false protection resulting from non-specific anti-cellular activities ([@BIB99]). Consequently, recent experimental FIV vaccine studies incorporated four approaches: (1) early passaged inoculum grown in primary peripheral blood mononuclear cells (PBMC); (2) molecularly cloned inoculum; (3) in vivo-derived inoculum; (4) contact challenges to simulate natural conditions ([@BIB114], [@BIB77], [@BIB56], [@BIB63]; [@BIB80]; [@BIB90]). Of the four approaches utilized, laboratory grown primary PBMC inoculum has proven to be the most reproducible and inexpensive approach. High titer cell-free purified inoculum can be readily produced in large quantities as laboratory grown inoculum which allows for an increased titer retention for a longer duration of time under cryopreservation. Thus, screening potential vaccines can be conducted efficiently and affordable with laboratory grown inoculum followed by limited testing of in vivo-derived inoculum.

In contrast to the laboratory grown inoculum approach, the in vivo-derived approach produced multiple limitations with inoculum production, titer retention, and increased costs, while the contact challenge studies approach produced limitations with feasibility, virus transmission, and increased costs. Limitations of in vivo-derived inoculum included: (1) the amount of inoculum produced was limited by the number of donor animals required to obtain the plasma or the cells at optimal viremic stage; (2) the high titers of virus were difficult to consistently achieve in vivo; (3) the production of in vivo-derived inoculum was more costly and technically more difficult to time the blood collection with peak viremia; (4) the biological effects of the plasma or the cellular component of the inoculum were more variable among the recipient animals. Limitations with contact transmission of FIV included: (1) potentially prolonged exposure periods (possibly 2--3 years) before sufficient seroconversion; (2) natural transmission dose may be too low for rapid transmission of FIV; (3) the route of FIV transmission may limit the rate of FIV transmission ([@BIB113], [@BIB80]).

Another approach is to use molecularly cloned FIV, SIV, and SHIV (SIV backbone with HIV Env and regulatory genes) as challenge inocula ([@BIB60], [@BIB56], [@BIB63], [@BIB41]). The use of such inocula has provided valuable information on the virology and pathogenesis of AIDS lentiviruses ([@BIB117], [@BIB73]). However, controversy has arisen on the use of such inocula as vaccine challenge, as was recently highlighted in experimental vaccine trial using SHIV challenge ([@BIB84], [@BIB37]). Underlying concerns with such cloned challenge inocula are that they do not mimic natural transmission and thus protection may be potentially easier to achieve than against primary isolates or wild type inocula consisting of quasi-species. Although the use of pathogenic cloned virus can provide rapid readout of vaccine-mediated protection from clinical disease, there are additional concerns that such pathogenic clones do not recapitulate the more prolonged course of HIV infection in humans ([@BIB84], [@BIB37]).

Many vaccines are designed to provide sterilizing immunity following administration. However, in the absence of sterilizing immunity, recent AIDS vaccine studies have advocated vaccine efficacy based on prevention of disease manifestations ([@BIB61], [@BIB83], [@BIB82]). Using high-dose challenge with virulent strains, a major reduction in both virus load and CD4 loss was observed in the disease-protected vaccinated animals compared to the unvaccinated animals ([@BIB8], [@BIB61], [@BIB83], [@BIB23], [@BIB82]). The duration of the reduced viral load is still unknown ([@BIB61], [@BIB82]). High-dose in vivo inoculum and/or early passages of select FIV strains have consistently caused clinical illness in addition to CD4 loss and CD4/CD8 inversion ([@BIB11], [@BIB22]). The use of a high-dose challenge or a highly virulent challenge strain may require modifications in the standard of judging vaccine efficacy, since no vaccine may be able to provide complete protection against such a rigorous challenge. Vaccine efficacy evaluation should be based on the effect on virus load, CD4 counts, CD4/CD8 ratio, and specific FIV antibody titer for active infection.

A controversy currently exists over the frequency of vertical transmission in experimental conditions and of transmission in domestic cats in nature. Serosurveys of young kittens suggest that vertical transmission of FIV is uncommon ([@BIB113], [@BIB67]). Direct exposure to FIV-positive saliva or blood via bite wounds is considered to be the major mode of natural transmission. Other transmission modes include exposure to contaminated body fluid (saliva or blood) during grooming and sharing of communal food ([@BIB67]). This observation is supported by findings from experimental studies using oral inoculation with FIV-infected culture fluid or blood ([@BIB25], [@BIB87], [@BIB9]). The oral inoculation dose needed for infection was much higher compared to the dose required for parenteral (intravenous and intraperitoneal) inoculation ([@BIB25], [@BIB87], [@BIB9]). Intravenous (IV) inoculation required the smallest inoculum dose ([@BIB25], [@BIB44]). Thus, natural FIV transmission is limited by the dose present in saliva and peripheral blood combined with the route of exposure. As seen in experimental contact studies, salivary FIV levels may be too low for rapid transmission. FIV blood levels may be sufficiently higher than FIV saliva levels, but exposure to blood is limited by the presence of open lesion(s) or of appropriately aggressive behavior. Exposing intact SPF male cats to naturally infected cats with oral lesions or to naturally infected intact male cats may increase the rate of transmission. However, contact exposure studies with only intact male cats may raise ethical issues. Nevertheless, epidemiological surveys of FIV-positive cats suggest that FIV infections occur more frequently in male cats (3:1 ratio) compared to female cats and in stray cats compared to household cats, supporting the current view that male cat aggressive behavior is a predisposing factor to infection. These contact studies are essential to determine the value of FIV vaccines in protecting cats from natural transmission.

Compared to other feline viruses (FeLV, FIP, feline herpes virus), contact transmission of FIV requires long-term exposure (months to years) with natural infected cats. According to contact studies and epidemiological surveys, disease manifestation is not common during the early phases of natural infection, supporting the view that natural transmission occurs at low doses ([@BIB43], [@BIB80]). In addition to a prerequisite prolonged exposure period, questions also arise concerning the dose requirements for natural transmission which remains elusive, the virulence of natural occurring populations, and the maintenance of high virus loads in body fluids of different FIV strains as opposed to laboratory strains. Consequently, a moderate approach using the appropriate FIV isolate and dose to produce CD4 decrease (12--24 weeks post-inoculation) without CD4/CD8 inversion, may be necessary to realistically approximate natural transmission and initially screen individual cats for infection. Although contact challenge studies (natural transmission) may not be feasible for commercial vaccine validation due to the prolonged exposure period, these obstacles should not preclude researchers from testing commercial vaccines against contact challenges since contact challenge systems closely mimic natural conditions. Reproducible, independent, scientific studies will become increasingly important in the future for improving the quality of new commercialized vaccines and established vaccines.

7. Conflict with current FIV diagnostic tests
=============================================

Unlike the standard FeLV diagnostics which detect viral antigen in body fluids (blood and tears), current FIV diagnostics rely on the detection of FIV antibodies in the peripheral blood ([@BIB30], [@BIB44]). FIV infection does not release sufficient levels of virus in circulation for conventional enzyme immunoassays (EIA) to detect viral antigens consistently. Sensitive PCR-based assays have been used to detect FIV infection in experimentally infected cats ([@BIB107], [@BIB64], [@BIB65], [@BIB89]). The sensitivity and specificity of these assays should be compared to FIV antibody-based commercial assays prior to use due to the expense of these sensitive assays compared to conventional assays. The recent approval of a PCR-based assay for HIV-1 diagnostics sets the precedent for use of such assay systems as an additional test to the antibody-based assays (antibody-specific EIA assays and confirmatory Western blot analysis) in current use ([@BIB7]). The impact to the current antibody-based FIV diagnostics will vary according to the type of FIV vaccine released for commercial use. The conventional inactivated FIV vaccine, for released this year, has a major conflict with current FIV diagnostics including the confirmatory Western blot analysis ([Fig. 1](#FIG1){ref-type="fig"} ). This vaccine, depending on the antigenic level of the commercial vaccine, induces broad spectrum antibody production to different FIV proteins with long-lasting titers. However, if appropriately inactivated, this vaccine will not result in viral antigen or genome production and will not conflict with PCR-based assays or conventional antigen-specific EIA assays. In contrast, live attenuated vaccines can cause significant conflict with current commercial FIV diagnostics. Also, potential conflicts may arise with future viral PCR- or protein-based diagnostics depending upon the level of attenuation. Since the current approach for testing attentuated FIV vaccines is based on viral regulatory gene deletion mutants, the attentuated virus will contain genes for viral structural proteins which are detectable by current FIV diagnostics. If improperly or insufficiently attenuated vaccines are used on immunocompromized hosts, the vaccine virus may escape the host compromized immune system and produce sufficient vaccine virus in circulation to interfere with current as well as future diagnostics.Fig. 1FIV immunoblot and commercial FIV test results of cats immunized with the dual-subtype FIV vaccine or experimentally infected with FIV~PET~ (20 CID~50~). Sera tested for FIV antibodies were from cats (two each) experimentally immunized with two different sources of dual-subtype FIV vaccine (immunoblot/Snap Combo lanes A, B, C and D) or experimentally infected with FIV (immunoblot/Snap Combo lanes E and F). These sera were tested for the presence of FIV antibodies using immunoblot analysis and commercial Idexx Snap^TM^ Combo (FeLV and FIV) Test Kit. The immunoblot analysis was performed at serum dilution of 1:100 using a published method ([@BIB90]) and the Snap test was performed as recommended by the Idexx Laboratories, Inc. Dual-subtype FIV vaccine produced by Fort Dodge Animal Health commercial company (USDA approved product) (lanes A and B) and those produced by our laboratory (lanes C and D) are shown for comparison. Immunogenicity and efficacy of our dual-subtype FIV vaccine has been previously reported ([@BIB90]). Both Snap test and immunoblot results demonstrate that vaccinated cats will develop antibodies reactive to current FIV diagnostics. Both vaccinations induced antibodies to the full spectrum of FIV antigens, including antibodies to the envelope (gp95). Interestingly, the cats immunized with the USDA approved dual-subtype FIV vaccine had more consistent and long-lasting antibodies to the envelope compared to cats immunized with our experimental dual-subtype FIV vaccine (2 of 2 cats vs. 1 of 2 cats positive after 1 year post-vaccination).

Most veterinary virus vaccines are either conventional inactivated whole virus or live attenuated virus vaccines ([@BIB105]). In the last 5 years, live recombinant vectored vaccines have been introduced to the veterinary market ([@BIB116], [@BIB105], [@BIB108]). Most notable and most widespread veterinary vectored vaccines are the rabies vaccine vectored by vaccinia, fowlpox, and canarypox viruses which are not virulent in unnatural hosts. These recombinant vectored vaccines incorporate gene sequence(s) of the targeted viral protein in the vector genome region that does not interfere with the targeted gene expression ([@BIB92]). The incorporated gene(s) must include genes for protective FIV epitopes and must be expressed at a sufficient level for the vaccinated host to mount a specific immune response. Predominant CTL and VN antibody epitopes reside on FIV Gag proteins and envelope glycoproteins, respectively ([@BIB75], [@BIB24], [@BIB33]). These viral proteins also make up over 75% of the structural proteins and contain the major epitopes for immunodiagnostics. Although vectored vaccines are generally known for their ability to generate cellular immunity compared to humoral immunity, specific antibodies against targeted virus can be produced using this vaccine system. Thus, modifications in current FIV diagnostic tests must be made for detection of FIV antibodies to viral proteins of active infection instead of FIV antibodies present on the targeted gene products expressed by the vaccine vector. In contrast, recombinant vectored vaccines will have minimal to no conflict with viral PCR- and protein-based diagnostics if the vector virus used preferentially infects the above described non-leukocytes (avian pox viruses) and the targeted protein(s) are not released into circulation.

8. Summary: impact of FIV vaccine to AIDS vaccine development and feline medicine
=================================================================================

Since the discovery of FIV in 1986, the goals of the FIV vaccine studies have been: (1) to identify effective vaccine designs which may serve as models for effective HIV vaccine designs in humans; (2) to develop an effective FIV vaccine for pet cats. Recent United States Department of Agriculture approval ([@BIB106], [@BIB35]) of Fel-O-Vax FIV, a dual-subtype FIV vaccine, has led to the commercial release of this vaccine by Fort Dodge Animal Health (FDAH, Fort Dodge, IA) on 14 July, 2002. Without an additional boost, the protection rate of this dual-subtype FIV vaccine after 1 year is 67% (18/27 cats) against an intramuscular heterologous FIV challenge ([@BIB35]. The same challenge inoculum resulted in a 74% infection rate (25/34 cats) in unvaccinated control cats. In the second trial using a slightly modified vaccine and immunization schedule (i.e., 8 instead of 12 weeks old kittens), the protection rate for vaccinated kittens rose to 84% (21/25 cats) after the same heterologous challenge compared to 90% infection rate (17/19 cats) in the unvaccinated control cats after 1 year ([@BIB36]). Although the vaccine appears to provide immunity for at least 1 year, contact exposure trials that simulate natural transmission are needed which compliment the parenteral challenge inoculations performed by FDAH.

As a consequence of the FeLV vaccine-associated fibrosarcoma, release of a commercial veterinary FIV vaccine will raise similar concerns. The policies adopted by veterinary practitioners for FeLV vaccine administration will probably be applied to FIV vaccine administration. The impact on the current FIV diagnostic tests will be an important issue requiring careful monitoring by practitioners. FIV diagnostics, requiring molecular technology to develop advanced assays with increased sensitivity and specificity, must keep abreast with the development and release of new commercial FIV vaccines. Equally as important to developing and commercially producing a reliable, safe, and efficacious vaccine for the veterinary community, FIV researchers must continue to educate the AIDS community about and promote the value of an FIV vaccine model for HIV vaccine development.

This work was funded by NIH R01 AI30904 and JKY Miscellaneous Donors Fund. Dr. Yamamoto is the inventor of record on a University of Florida held patent and may be entitled to royalties from companies that are developing commercial products that are related to the research described in this paper.

[^1]: Commercial Fort Dodge adjuvant (FD-1); cholera toxin (CT); incomplete Freund's adjuvant (IFA); microfluidized oil/water emulsion (MF59.0); FIV proteins coated onto biotinylated homologous RBC (Homol-RBC).

[^2]: FIV-Petaluma (PET); FIV-Shizuoka (SHI); FIV-Glasgow 8 (GL8); FIV-Milan 2 (M2).

[^3]: Rectal (rect); intranasal (in); intravaginal (ivag); oral (po); rectal immunization followed by either i.p. or in (±i.p., in) immunization; s.c. immunization followed by either ivag or po immunization (±ivag, po) on week 20.

[^4]: FIV-Amsterdam 6 (AM6).

[^5]: Reference (Ref.).

[^6]: 20 week boost was given at 200mg of either IFA or cholera toxin (IFA/CT) as adjuvant using s.c. immunization followed by either intravaginal (s.c./ivag) or oral (s.c./po) immunization.

[^7]: Four controls each were immunized with either IFA alone or IFA with CT boost on 20 weeks. Only combined result of the controls was available.

[^8]: The four protected cats from above study were boosted with the same vaccine, while four new control cats were immunized with BSA biotinylated homologous RBC. Both groups were challenged with the same inoculum at the same dose as above.

[^9]: Statistically significant difference from control when *P*\<0.05.

[^10]: Infected-cell vaccine and uninfected cells were inactivated by fixation with paraformaldehyde; FIV-PET infected feline T-cell line (FL-4) and uninfected feline T-cell line (FeT-J) developed by USA group; feline PBMC cell line (MBM) developed by Italian group; autologous peripheral blood mononuclear cells (autoPBMC); FIV envelope/Gag-protease (env/gag-pr) gene construct of canarypox virus vector (ALVAC-FIV) was grown in chicken embryo fibroblast (CEF); infected-cell vaccine (ICV) consisted of PET infected FL-4 cells; plasmid pCI vector construct of FIV nucleocapsid (pCI-NC vector); recombinant surface Env protein (recSU) expressed in *E. coli* system.

[^11]: Quillaja saponin adjuvant (Quil A); incomplete Freund's adjuvant (IFA); syntax adjuvant formulation muramylpeptide (SAF-MDP).

[^12]: FIV-Petaluma (PET); FIV-Millan 2 (M2); infectious molecular clone (19k1) of FIV-AM19; FIV-Ville Franche (VFr); FIV-Gasser (GAS); FIV-Bangston (BANG) has Gag of clade A and Env of clade B (A/B).

[^13]: Targeted lymph node (TLN); intranasal (in).

[^14]: Rectal (rect); contact exposure (contact expo) with field cats infected with FIV; field isolates (field isol); information not available (na).

[^15]: Percent protection (% protect); enhanced challenge virus load (↑) observed in this immunization group.

[^16]: Reference (Ref.).

[^17]: Immunized twice with either ALVAC-FIV or ALVAC vector (1×10^8^pfu) followed by 1× immunization with ICV (+1×10^8^ cell).

[^18]: Three protected cats from above boosted with ICV and then challenged second time with distinctly heterologous FIV-BANG.

[^19]: Immunized 2× with either pCI vector or pCI-NC vector on days 0 and 15 followed by 2× immunization with recSU on days 30 and 45.

[^20]: 29 aa acid peptide to second conserved (C2) region of FIV surface Env; multiple antigenic peptide V3 region (MAP) of surface Env; palmitoyl thioester V3 peptide (ptV3); V3 region (V3) of surface Env; solubilized FIV-AM19 from infected CrFK cells (swFIV); recombinant vaccinia virus expressed Env glycoprotein of AM19 from which the cleavage site between SU and TM proteins (SU+TM); FIV Gag protein derived from FIV-AM19k1 (19k1) sequence; solubilized CrFK cell proteins (swCrFK); simian immunodeficiency virus Env (SIV-Env); phosphate buffered saline (PBS); recombinant surface Env (recSU) expressed either by *E. coli* or baculovirus expression system.

[^21]: Quillaja saponin adjuvant (Quil A); cholera toxin (CT); incomplete Freund's adjuvant (IFA); immune stimulating complexes (ISCOMs); all proteins formulated in ISCOMs (all); aluminum hydroxide (AlOH); stimulon saponin adjuvant (QS-21); Freund's complete adjuvant (FCA); rabies nucleocapsid (rabNC).

[^22]: FIV-Glasgow 8 (GL8); FIV-Petaluma (PET); FIV-Amsterdam 19 (AM19); infectious molecular clone (19k1) of AM19; FIV-Zurich 2 (Z2).

[^23]: Mucosal (m) CID~50~.

[^24]: Percent protection (% protect.); decreased FIV challenge load (↓) observed in this immunization group.

[^25]: Reference (Ref.).

[^26]: Targeted lymph node (TLN); all rectal immunization or rectal immunization followed by i.p. boosts (±i.p.); intranasal (in); all rectal immunization or rectal immunization followed by in boosts (±in).

[^27]: FIV integrase gene deleted (DIN) proviral DNA; FIV reverse transcriptase gene deleted (DRT) proviral DNA; controls consist of either plasmid (pBR328), PBS, carrier (gold particle), culture media (media), adjuvant (adjuv), or no immunization (none); plasmid pBR328 used for proviral DNA construct; minimalistic, immunogenic defined gene expression (MIDGE) vector construct of FIV Env gene (gp140 DNA) coated onto gold particles; AP-1 binding site deleted infectious molecular clone (proviral DNA DAP-1).

[^28]: Molecular adjuvantation with either interleukin 18 (IL-18 DNA), IL-12 plus IL-18 (IL12/IL18 DNA), and interferon-g (IFN-g DNA).

[^29]: FIV-Glasgow 8 (GL8); FIV-Zurich 2 (Z2); FIV-San Diego PPR (PPR), FIV-Petaluma (PET); infectious molecular clone of PET (F-14); FIV-TM2 (TM2) from Japanese group.

[^30]: Intraepidermal (i.e.); intravaginal (ivag).

[^31]: All the challenge strains are wild type without deletions.

[^32]: Decreased FIV challenge load (↓) observed in this immunization group as compared to control.

[^33]: Reference (Ref.).

[^34]: First immunization of vif gene deleted proviral DNA (DVIF) at 600mg followed by second immunization at 300mg; innoculated intravaginally with infectious molecular clone (proviral DNA AP-1) infected feline T-cell line (MYA-1).

[^35]: Single immunization with either pBR328 plasmid or PBS at the time when other vaccine groups received the last boost.

[^36]: Protected cats from above study received a second challenge (second) of PET and those protected from second challenge received a third challenge (third) of GL8.
